A federal judge in Illinois has allowed a generic drug company’s lawsuit to proceed against its pharmaceutical partners over accusations of delaying the development of critical drug medications. The lawsuit centers on the untimely progress of drug development, which the plaintiff asserts is a breach of their implied duty. The case sheds light on the complexities and potential pitfalls of partnerships within the pharmaceutical industry, particularly when timelines and mutual obligations are at stake. For more details, visit the original article here.